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Network Protocol 0303
Steven M. Devine,1 Shelly Carter,2 Robert J. Soiffer,3 Marcelo C. Pasquini,4
Parameswaran N. Hari,4 Anthony Stein,5 Hillard M. Lazarus,6 Charles Linker,7
Edward A. Stadtmauer,8 Edwin P. Alyea, III,3 Carolyn A. Keever-Taylor,4 Richard J. O’Reilly9Graft-versus-host disease (GVHD) is most effectively prevented by ex vivo T cell depletion (TCD) of the
allograft, but its role in the treatment of patients undergoing allogeneic hematopoietic cell transplantation
(HCT) for acute myelogenous leukemia (AML) in complete remission (CR) remains unclear. We performed
a phase 2 single-arm multicenter study to evaluate the role of TCD in AML patients in CR1 or CR2 up to age
65 years. The primary objective was to achieve a disease-free survival (DFS) rate of.75% at 6 months post-
transplantation. A total of 44 patients with AML in CR1 (n 5 37) or CR2 (n 5 7) with a median age of 48.5
years (range, 21-59 years) received myeloablative chemotherapy and fractionated total body irradiation
(1375 cGy) followed by immunomagnetically selected CD34-enriched, T cell‒depleted allografts from
HLA-identical siblings. No pharmacologic GVHD prophylaxis was given. All patients engrafted. The incidence
of acute GVHD grade II-IV was 22.7%, and the incidence of extensive chronic GVHDwas 6.8% at 24 months.
The relapse rate for patients in CR1 was 17.4% at 36 months.With a median follow-up of 34 months, DFS for
all patients was 82% at 6 months, and DFS for patients in CR1 was 72.8% at 12 months and 58% at 36 months.
HCT after myeloablative chemoradiotherapy can be performed in a multicenter setting using a uniform
method of TCD, resulting in a low risk of extensive chronic GVHD and relapse for patients with AML in CR1.
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Allogeneic hematopoietic cell transplantation
(HCT) is the most effective means for preventing re-
lapse in patients with acute myelogenous leukemia
(AML) in complete remission (CR) [1-5]. However,
both acute and chronic graft-versus-host disease
(GVHD) frequently occur after HCT and adversely af-
fect quality of life and overall survival [1,6-8]. GVHD is
most commonly prevented by pharmacologic therapy,
but is most effectively prevented by ex vivo T cell
depletion (TCD) of the allograft [9,10]. However, the
use of TCD is limited by logistical difficulties, lack of
a Food and Drug Administration (FDA)-approved
method, and concerns regarding potential risks of
graft rejection, posttransplantation infection, and
leukemic relapse. Nonetheless, several recent TCD
studies involving patients with AML suggest a low risk
of GVHD and relapse with this approach, particularly1343
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[11-15].
The goal of the present study was to determine
whether the encouraging results reported by single
centers could be reproduced in a multicenter setting.
We selected a TCDmethod that would remove almost
all T cells and thus eliminate the need for posttrans-
plantation pharmacologic GVHD prophylaxis. We
limited enrollment to adult patients with AML in first
CR (CR1) or second CR (CR2) and administered the
TCDgraft after an intensive pretransplantation condi-
tioning regimen, reasoning that the potentially unde-
sirable effects of TCD (eg, graft rejection, relapse)
would be reduced if combined with a conditioning
regimen that is highly immunosuppressive and antileu-
kemic. Our results demonstrate the feasibility and
effectiveness of this uniform approach.METHODS
Patients and Donors
Patients aged18-65yearswithadiagnosisofAMLin
first or second complete morphological remission (CR1
orCR2) according to InternationalWorkingGroup cri-
teria were eligible for this study [16,17]. Patients with
acute promyelocytic leukemia and t(15;17) or core
binding factor AML [M4Eo with inv16 and AML with
t(8;21)] in CR1 were not eligible. Patients had to have
a HLA-identical sibling donor willing to consent and
able to donate a granulocyte colony-stimulating factor
(G-CSF)-mobilized peripheral blood stem/progenitor
cell (PBSC) allograft and normal organ function, and
had to be HIV-negative.
Sibling donors had to be younger than 75 years,
weigh more than 25 kg, and be seronegative for human
immunodeficiency virus, hepatitis B/C virus, human
T-lymphotropic virus I/II, and syphilis. Both patients
and donors provided written informed consent in ac-
cordance with the Helsinki Declaration protocol for
a study approved by the institutional review board at
each participating institution. The study was also ap-
proved by the FDA under an Investigational Device
Exemption (BB-IDE#11965), held by the National
Heart, Lung, and Blood Institute, and was monitored
by an independent Data Safety and Monitoring Board
appointed by the National Heart, Lung, and Blood
Institute. The clinical trial is registered at Clinical
Trials.gov as NCT00201240.Conditioning Regimen
All patients received a conditioning regimen con-
sisting of hyperfractionated total body irradiation
(TBI) at a total dose of 1375 cGy given over 4 days
(on days -9, -8, -7, and -6) at a dose rate of\20 cGy/
minute. Doses of 125 cGy/fraction were administeredat a minimum interval of 4 hours between fractions, 3
times daily, for a total of 11 doses. Sequential doses of
TBI were administered in an anterior/posterior or
lateral orientation at the discretion of the radiation on-
cologists at each center, but the technique was kept
consistent within each institution. Compensators and
lung blocks yielding a minimum lung dose of 800
cGy were allowed based on institutional practice. After
TBI, thiotepa was administered at a dose of 5 mg/kg
(ideal body weight)/day i.v. for 2 days on days -5 and
-4, followed by cyclophosphamide 60 mg/kg (ideal or
adjusted body weight)/day for 2 days (days -3 and -2).
A single 2.5 mg/kg dose of rabbit anti-thymocyte
globulin (Thymoglobulin; Genzyme, Cambridge,
MA) was given as an i.v. infusion over 6-8 hours on
day -4.
Donor Mobilization and TCD Procedures
Donors received at least 5 consecutive doses of
G-CSF 10-16 mg/kg once daily by s.c. injection. Leu-
kapheresis was initiated on day 5 of G-CSF therapy.
Tomaximize the CD341 cell dose transplanted, 2 con-
secutive days of leukapheresis (days 5 and 6) were
planned for all donors. A third day of leukapheresis
was allowed if necessary to ensure infusion of a mini-
mum CD341 cell dose (see the next section).
CD341 cell selection with the Miltenyi Clini-
MACS device (Miltenyi Biotec, Bergisch Gladbach,
Germany) was the sole method of TCD used in this
clinical trial. TCD was performed in accordance with
procedures outlined in the CliniMACS user’s operat-
ing manual, as well as institutional standard operating
procedures validated at each study site. Leukapheresis
products were either processed on the same day as col-
lected or refrigerated overnight (at 1-8C) and pro-
cessed the next morning.
Target Allograft Composition
The target allograft cell composition following
TCDwas aCD341 cell dose of$5.0 106/kg recipient
weight in combination with a CD31 cell dose\1.0 
105/kg recipient weight. A CD341 cell dose of 1.0 
106/kg was the absolute minimum at which a recipient
could still be considered evaluable for study endpoints.
If thisminimal dosewas not achieved after 2 days of leu-
kapheresis, thendonors underwent a third collection. In
that case, cells from the third collection were not to be
CD341-selected. CD341-selected allografts were
transplanted in accordance with institutional protocols
on day 0 and sometimes also on day11 post-HCT.
Supportive Care and Patient Assessment
The protocol specified that no posttransplantation
pharmacologic GVHD prophylaxis would be given as
long as the CD31 cell dose transplanted was\1.0 
105/kg. Hematopoietic growth factors were not
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virus (CMV) surveillance was performed weekly with
either quantitative polymerase chain reaction or anti-
genemia assay through day 1100, and preemptive
treatment was initiated as required according to insti-
tutional guidelines. Surveillance for Epstein-Barr virus
(EBV) infection was performed weekly using a real-
time quantitative EBV DNA polymerase chain reac-
tion plasma-based assay through day 1100 and then
monthly up to day 1180. EBV assays were sent from
each center to a centralized laboratory at the Univer-
sity of Washington [18]. Patients with a blood EBV
DNA concentration of .1000 copies/mL on any test
were scheduled to receive preemptive rituximab at
375 mg/m2 for at least 1 dose; rituximab was continued
weekly if the concentration remained .1000 copies/
mL after the first dose.
Acute and chronicGVHDwere graded according to
established criteria [19,20]. Patients were considered
evaluable for GVHD if they engrafted. Organ toxicity
was graded according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events
version 3.0.
Donor hematopoietic chimerism was assessed on
samples of unmanipulated bone marrow as well as on
separated T cells (CD31) from peripheral blood
obtained on days 128, 1100, 1180, and 1365 using
standard methods at each institution. Peripheral blood
samples also were obtained for standard lymphocyte
immunophenotyping at the same time points. No do-
nor leukocyte infusions or other interventions were
planned based on the results of the chimerism analyses.Definitions
Neutrophil engraftment was defined as an increase
in absolute neutrophil count to$500/mL for 3 consec-
utive days following a conditioning regimen-induced
nadir. Platelet engraftment was defined as the first
day of 3 consecutive platelet count measurements
.50,000/mL without the aid of transfusion for 7 con-
secutive days. Primary graft failure was defined as fail-
ure of neutrophil engraftment by day 130. Secondary
graft failure was defined as primary engraftment fol-
lowed by a subsequent decline in the absolute neutro-
phil count to\500/mL with no apparent cause, such as
drugs or opportunistic infection, and unresponsive to
hematopoietic growth factor therapy.
TheSouthwestOncologyGroup/EasternCoopera-
tive Oncology Group classification system was used to
categorize the risk of relapse in patients with AML in
CR1 based on cytogenetic findings [4]. Abnormalities
not included in theSouthwestOncologyGroup/Eastern
Cooperative Oncology Group definition were catego-
rized according to the Cancer and Leukemia Group B
classification system [21]. Patients with a normal karyo-
type at diagnosis found to have a Flt3 internal tandemduplication mutation were placed in the intermediate-
risk cytogenetic category but were categorized as being
at high risk for relapse based on previous studies [22,23].
Statistical Considerations
This study was a phase II single-arm multicenter
trial with a primary objective of determining the
disease-free survival (DFS) probability at 6 months
post-HCT. This early DFS time point was chosen to
begin planning for a follow-up trial to compare this ap-
proach with other GVHD prophylaxis strategies if the
results appeared promising. DFS was defined as the
minimum time from HCT to relapse or death, with
censoring if the patient was alive and disease-free by
May 10, 2010. The anticipated 6-month DFS proba-
bility was 75%, and the lower boundary for proceeding
to a phase III trial was aDFS probability of.0.55. The
primary hypothesis can be described asHo: P#.55 ver-
sus H1: P..55.When the true DFS percentage is 75%
with a sample size of 45, there is 84% power at a5 .05
to rule out a DFS percentage of\55%. Overall sur-
vival (OS) was defined as the time fromHCT to death,
with censoring if the patient was alive at the data cutoff
date.
Kaplan-Meier estimates were computed for DFS
and OS, with Greenwood’s formula as the variance es-
timate [24]. Cumulative incidence curves incorporat-
ing death as a competing risk were computed for
time to neutrophil and platelet engraftment, relapse,
and acute and chronic GVHD [25]. The cumulative
incidence of TRM was calculated with relapse as
a competing risk. All calculations were performed us-
ing SAS version 9.1.2 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Patient and donor characteristics are presented in
Table 1. A total of 47 patients were enrolled at 8 cen-
ters between October 2005 and December 2008.
Three of these patients were enrolled but did not pro-
ceed to transplantation on this study due to withdrawal
of informed consent (n5 2) or disease progression be-
fore the onset of conditioning (n 51); these 3 patients
are not discussed further in this report. A total of 44
patients underwent HCT in this study.
Apheresis Products and Graft Processing
A total of 84 products were processed for the 44 pa-
tients who underwent HCT. Products from multiple
days of collection were pooled for CD34-enrichment
in 2 cases, and products from a single collection were
split for enrichment on 2 columns in 4 cases. The re-
sults of the CD341 cell selection processing are pre-
sented in Table 2. All patients received .2.0  106
Table 1. Recipient and Donor Characteristics
Age, years, median (range) 48.5 (21-59)
Patient age by decade, n
<20 0
20-29 7
30-39 4
40-49 14
50-59 19
Sex, n
Male 16
Female 28
Performance status (KPS), n
100% 17
90% 17
80% 8
70% 2
Leukemia stage, n
CR1 37
CR2 7
Race, n
White 42
Other 2
Cytogenetic risk (CR1/CR2), n
Favorable 0/1
Intermediate 26/2
Unfavorable 11/3
Unknown 0/1
Recipient CMV serostatus
positive/negative, n
17/27
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patient received more than the targeted CD31 cell
dose of 1.0  105/kg.Engraftment and Chimerism
All patients engrafted neutrophils and platelets, at
a median of 12 days (range, 9-19 days) and 16 days
(range, 13-159 days) posttransplantation, respectively.
There were no primary graft failures. One female pa-
tient who underwent HCT while in CR1 using
a male donor developed secondary graft failure on
day 154 and later died of fungal pneumonia. No pa-
tient received a donor leukocyte infusion. Donor chi-
merism values are given in Table 3. The degree of
donor chimerism was not predictive of relapse.Immune Reconstitution
Quantitative recovery of lymphocytes is depicted
in Figure 1. CD41 and CD81 reconstitution wasTable 2. Results of CD34 Enrichment Procedures
TNC/product CD34 selected 7.2  1010 (2.1-15.5)
TNC processed/patient 13.4  1010 (5.4-26.9)
Total CD34 dose processed/patient 10.0  108 (2.9-34.6)
Final CD34 dose/kg transplanted 7.9  106 (2.4-31.3)
CD34 yield (%)/product CD34 selected 65.5% (27.2-125.5)
CD34 purity (%)/product CD34 selected 96.7% (61.5-99.8)
Total CD3 dose processed/patient 3.2  1010 (1.3-8.5)
Final CD3 dose/kg transplanted 6.6  103 (1.1-84.9)
Log10 T cell depletion/product CD34 selected 4.9 (3.2-5.9)
Data are median and range. The total number of products CD34
selected was 84.slow, with median levels\200/mL until 1 year post-
HCT.Acute and Chronic GVHD
All patients were evaluable for acute GVHD. Ten
patients developed grade II (n 5 8) or III (n 5 2)
acute GVHD, and 10 patients developed grade I acute
GVHD.No patient developed grade IV acute GVHD.
Of the patients with grade II or III acute GVHD, 7 had
gastrointestinal (GI) involvement (including 3with up-
per GI involvement only), 6 had cutaneous involve-
ment, and 2 had liver involvement. The median time
to onset of any acute GVHD was 23 days (range, 14-
100 days). The cumulative incidence of acute GVHD
grade II-IV at 100 days was 22.7% (95% confidence in-
terval [CI], 10.2%-35.3%) (Figure 2A). The cumula-
tive incidence of acute GVHD grade III-IV at 100
days was 4.5% (95% CI, 0-10.8%) (Figure 2B). Eight
patients developed chronic GVHD, at a median of
129 days post-HCT (range, 109-391 days). Chronic
GVHDwas limited in 5 patients and extensive in 3 pa-
tients. The cumulative incidence of any chronic
GVHD was 19.0% at 24 months (95% CI, 6.8%-
31.1%) (Figure 2C), and the cumulative incidence of
extensive chronic GVHD was 6.8% (95% CI,
0-14.4%) at 24 months.Opportunistic Infections
Thirty-four of the 44 patients (77%) experienced
at least 1 documented infection. Bacterial infections
were observed in 27 patients (61%); invasive fungal in-
fections in 5 patients (11%); and viral infections (CMV
or EBV) in 25 patients (57%). CMV viremia requiring
preemptive treatment was observed in 11 patients
(32%). Twenty-one patients were considered at high
risk for CMV reactivation due to being CMV-
seropositive (n5 17) or, if CMV-seronegative, having
a seropositive donor (n5 4). Nine of these 21 patients
(43%) developed CMV viremia. Eight patients (18%)
developed EBV viremia (.1000 copies/mL), at a me-
dian of 114 days (range, 34-349 days) post-HCT, re-
quiring at least 1 dose of rituximab (one 375-mg/m2
dose in 7 patients and 4 doses in 1 patient). One patient
developed posttransplantation lymphoproliferative
disorder (PTLD) with a large-cell lymphoma involv-
ing the liver and died secondary to progressive donor
cell–derived EBV-related PTLD on day175. The cu-
mulative incidence of EBV viremia at 12 months was
18.2% (95% CI, 6.6%-29.7%).Nonhematologic Toxicity
Themost common grade 3-5 nonhematologic tox-
icities related to the conditioning regimen were GI
(mucositis/stomatitis) and pulmonary (Table 3).
Table 3. Results of Transplantation
Hematopoietic engraftment, days, median (range)
Neutrophils 12 (9-19)
Platelets 16 (13-159)
Hematopoietic chimerism, donor %, median (range)
T cell
Day +28 95 (0-100)
Day +100 71 (0-100)
Day +180 80 (11-100)
Day +365 95 (0-100)
Myeloid
Day +28 100 (75-100)
Day +100 100 (69-100)
Day +180 99 (8-100)
Day +365 100 (80-100)
Nonhematologic toxicity, % (grade) or number
Mucositis/stomatitis 34% (3)
5% (4)
Pulmonary 7% (3/4)
5% (5)
Hepatic veno-occlusive disease 5% (mild)
2% (moderate)
Thrombotic microangiopathy 2% (4)
Hemodialysis n 5 2
Seizures n 5 1
Acute GVHD (grade), cumulative incidence, % (95% CI)
II-IV 23 (10-35)
III-IV 5 (0-11)
Chronic GVHD at 24 months, cumulative
incidence, % (95% CI)
Limited/extensive 19 (7-31)
Extensive only 7 (0-14)
Relapse, cumulative incidence, % (95% CI)
All patients
12 months 21 (8-33)
36 months 24 (11-37)
CR1 only
12 months 14 (2-25)
36 months 17 (4-30)
CR2 only
12 months 57 (15-99)
36 months 57 (15-99)
TRM, cumulative incidence, % (95% CI)
12 months 14 (3-24)
36 months 23 (9-37)
DFS, Kaplan-Meier estimate, % (95% CI)
All patients
6 months 82 (70-93)
12 months 66 (52-80)
36 months 53 (37-69)
CR1 only
12 months 73 (58-87)
36 months 58 (40-76)
CR2 only
12 months 29 (0-68)
36 months 29 (0-68)
OS, Kaplan-Meier estimate, % (95% CI)
All patients
12 months 77 (65-90)
36 months 56 (40-73)
CR1 only
12 months 81 (68-93)
36 months 60 (42-78)
CR2 only
12 months 57 (17-98)
36 months 38 (0-84)
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Nine patients died from causes other than relapse,
at a median of 188 days (range, 60-762 days) post-
HCT. The cumulative incidence of transplantation-
related mortality (TRM) was 14% (95% CI,3.4%-24%) at 12 months, 20% (95% CI: 7.1-32.7) at
24 months, and 23.2% (95% CI: 9.3-37.1) at 36
months (Table 3).
Relapse, DFS, and OS
Themedian follow-up for all surviving patients was
34 months (range, 11.5-51.5 months). Ten patients
relapsed (6whounderwentHCT inCR1 and4whoun-
derwent HCT in CR2), at a median of 198 days post-
HCT (range, 74-664 days). The cumulative incidence
of relapse for the entire group was 20.6% (95% CI,
8.4%-32.8%) at 12 months and 23.7% (95% CI,
10.5%-37%) at 36 months (Figure 3). Of the 10 pa-
tients who relapsed, 4 had intermediate-risk cytogenet-
ics, 5 had high-risk cytogenics, and 1 had unknown
cytogenics. The DFS rate at 6 months post-HCT was
81.8% (95% CI, 70.3%-93.4%) for the entire group.
DFS and OS by stage are given in Tables 3 and
Figure 4. Themost common cause of death was relapse
(Table 3).DISCUSSION
These results demonstrate for the first time in
a prospective multicenter setting that a strategy com-
bining intensifiedmyeloablative conditioning followed
by transplantation of CD34-enriched, T cell‒depleted
PBSCs from HLA-identical sibling donors can result
in consistent engraftment with a low risk of severe
acute and chronic GVHD (\10% for both) and
a low risk of relapse in patients with AML in CR1.
Wechoseamethod forTCDthat uses immunomag-
netic selection of CD34-expressing cells based on previ-
ous studies that suggested reliable CD34 yields, high
CD34 purity, and vigorous TCD [11,12,26,27]. The
device (Miltenyi CliniMACS) was made available
through an Investigational Device Exemption filed
with the FDA. We have demonstrated that this method
is highly reproducible from center to center, resulting
in a consistently high degree of CD34 purification,
TCD, and sterility. The CD34-enrichment procedure
resulted in amedianCD3 depletion of 4.9 logs. In all re-
cipients, the CD3 dose was below the protocol-specified
limit of 1 105/kg.The resulting low risk of grade II-IV
and particularly grade III-IV acute GVHD despite the
absence of pharmacologic GVHD prophylaxis suggests
that this threshold T cell dose is appropriate in the
HLA-matched sibling setting [28]. Although about
40% of patients still developed some acute GVHD, 13
of the 20 patients with acuteGVHDhad only cutaneous
involvementwhichwasmanageablewith corticosteroids.
Further study is needed to determine whether this same
threshold CD3 dose can be used in recipients of CD34-
enriched unrelated donor PBSC grafts.
The median CD34 dose transplanted in this study
was 7.9  106/kg, and, notably, 86% of the recipients
Figure 1. Recovery of lymphocytes by day posttransplantation. Values are expressed as median 6 standard error. Shaded areas represent the 25th-
75th percentile range for normal individuals. (A) CD41 cells. (B) CD81 cells. (C) NK cells (CD561 cells). (D) B cells.
1348 Biol Blood Marrow Transplant 17:1343-1351, 2011S. M. Devine et al.were able to achieve the target CD34 dose of 5.0 
106/kg. This resulted in a primary engraftment rate
of 100%. One patient experienced secondary graft fail-
ure despite receiving an initial CD34 dose of 10.1 
106 CD341 cells/kg. The pathophysiology of second-
ary graft failure is complex, and multiple factors may
contribute to this event. Overall, the risk of primary
or secondary graft failure was very low in this trial,
supporting our choice of target CD34 cell dose.
The incidence of severe or life-threatening condi-
tioning regimen‒related toxicity was relatively low in
this trial, suggesting that the regimen was generally
well tolerated despite the median patient age of 48.5
years. The most common early toxicity was mucositis.
The most serious toxicity was pulmonary-related,
typically occurring between 30-100 days post-HCT.
Within the first 100 days after HCT, 14% of the
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Figure 2. Cumulative incidence of grade II-IV acute GVHD (A), gradepossibly attributed to the conditioning regimen.
Idiopathic pneumonia syndrome is a well-described
regimen-related toxicity associated with various high-
dose conditioning regimens [29]. Overall, the rate of
pulmonary complications observed in this trialwas sim-
ilar to or lower than the rates reported in previous trials
in which myeloablative conditioning was used [30,31].
Interestingly, 1 study found an association between
TCD and a lower risk of pulmonary complications
compared with standard GVHD prophylaxis [31].
The rates of bacterial, fungal, and CMV infections
encountered in the present trial did not appear to be
any greater than those reported after conventional
PBSC transplantation [1,32]. The low rates of acute and
chronic GVHD and the absence of immunosuppressive
drugs also may play roles in limiting opportunistic
infections [33].One exception is the risk of EBV reactiva-
tion, which is increased in recipients of T cell‒depletednsplant Month Post Transplant 
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ofEBVviremia requiring at least 1 dose of rituximab, and
1 patient died from PTLD. Thus, close monitoring for
EBV infection is imperative at least up to day1100 in re-
cipients of CD341-enriched allografts, because early6 3 8 2 0 2 2 1 8 4 0 2 3 4 2 6 1 
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remission state (D).treatment with rituximabmay be able to reverse this con-
dition in a high proportion of cases.
Relapse remains the major cause of death in pa-
tients receiving allografts for high-risk AML
[1,2,4,5,35]. Because CD34 enrichment results in
a TCD of 4-5 logs, there is a concern that it might
decrease the putative graft-versus-leukemia effect
[36]. Although this has been demonstrated clearly in
patients with chronic myelogenous leukemia, there is
no convincing evidence of higher relapse rates after
TCD HCT for AML in remission [10,36-38]. The
cumulative incidence of relapse in CR1 of\20% at 3
years suggests either the retention of a graft-versus-
leukemia effect or, alternatively, the highly effective
antileukemic nature of the conditioning regimen
used. It is more difficult to comment on the observed
risk of relapse in patients with AML in CR2, because
of our low patient numbers. Only 7 patients in this trial
underwent HCT while in CR2, 4 of whom relapsed.
These results are in contrast to previous reports sug-
gesting favorable outcomes after TCD HCT for
AML patients in CR2 [13,14,39]. We cannot draw
any definitive conclusions for this group at this time;
further investigation is needed to define the relapse
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1350 Biol Blood Marrow Transplant 17:1343-1351, 2011S. M. Devine et al.Although the transplantation of PBSCs may miti-
gate complications early after HCT, late complica-
tions related to chronic GVHD appear to be more
common. A recent meta-analysis of 9 randomized
trials comparing PBSCs and bone marrow clearly
demonstrated a higher risk of extensive chronic
GVHD after transplantation of HLA-matched sibling
mobilized PBSCs [8]. The chronic GVHD observed
after PBSC HCT may be more difficult to treat and
may require a greater duration of corticosteroid use
compared with that seen in bonemarrowHCT, result-
ing in a higher risk of late complications [6,40]. In this
context, the very low risk of extensive chronic GVHD
observed in the present trial suggests another potential
advantage of this approach. The low risk of both
relapse and chronic GVHD makes this approach
attractive for selected high-risk patients with AML in
remission.
In conclusion, this study demonstrates that TCD
HCT after intensive myeloablative chemoradiother-
apy conditioning can be performed successfully in
amulticenter setting using a single TCDmethod with-
out additional posttransplantation pharmacologic
GVHD prophylaxis. The low incidences of relapse
and of acute and chronicGVHD in the absence of post-
transplantation prophylaxis are especially encouraging.
A second study to confirm these findings in unrelated
donor HCT is currently being planned by the Blood
and Marrow Transplant Clinical Trials Network.ACKNOWLEDGMENTS
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